Secondary analysis of the phase III PADA-1 trial (1,017 patients, HR+/HER2- advanced breast cancer): baseline blood ESR1 mutations were found in 3.2%, rising mutations were detected mostly after 6 months and before 3 years, and several factors were associated with detection.
Secondary analysisn = 1,017
Cabel et al. Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer